Smirnova E Iu, Sakhnin V I, Tatarinov P A, Postnikov S S, Kapranov N I, Shabalova L A, Uglitskikh A K, Stukalova A A, Voronkova A Iu, Simonova O I
Antibiot Khimioter. 1993 Feb-Mar;38(2-3):42-4.
Ciprofloxacin was used in treatment of 13 children aged 6 to 18 years with mucoviscidosis and exacerbation of the bronchopulmonary process. The dose of the drug was 20 to 30 mg/kg a day when administered orally or 15 mg/kg a day when administered at first intravenously and then orally. The treatment course averaged 14 days. The indications to the drug use were: severe processes of mucoviscidosis and chronic colonization of the bronchial mucosa and lung tissues with Pseudomonas aeruginosa (mucoid or nonmucoid form) sensitive to ciprofloxacin and resistant to other antibiotics. The trials showed that ciprofloxacin was highly efficient: the state of the patients improved and the inflammation index of the total blood count normalized. However, eradication of P. aeruginosa from the respiratory tracts was not observed. The drug allergy in 1 patient and a transient increase in the level of transaminases in 5 patients as the adverse reactions were recorded.
环丙沙星用于治疗13名6至18岁患有黏液黏稠病且支气管肺部病情加重的儿童。口服给药时药物剂量为每日20至30毫克/千克，先静脉给药然后口服时剂量为每日15毫克/千克。治疗疗程平均为14天。用药指征为：黏液黏稠病的严重病情以及支气管黏膜和肺组织被对环丙沙星敏感但对其他抗生素耐药的铜绿假单胞菌（黏液型或非黏液型）慢性定植。试验表明环丙沙星高效：患者状况改善，全血细胞计数的炎症指标恢复正常。然而，未观察到呼吸道中的铜绿假单胞菌被根除。记录到1例药物过敏和5例患者转氨酶水平短暂升高作为不良反应。
